

Curriculum Vitae

Surname WONG
Given Name Muh Geot
Phone (04)00854109 (M)
Email muhgeot.wong@sydney.edu.au

Career summary

I am an Associate Professor of Medicine, University of Sydney, Researcher and Educator, and a Senior Consultant Nephrologist at the Department of Renal Medicine, Concord Repatriation General Hospital. Since completing my PhD (Usyd) in June 2011, I strived to become an independent clinician-researcher with the aim to generate high quality data to support the prevention of chronic kidney disease and its complications. I have demonstrated research capacity, being awarded several National and philanthropic grants to a combined value of ~\$6M. I have an excellent publication track record. I have supervised to completion 2 PhD students and 2 Masters students. In addition, I have been central to a number of large-scale randomised controlled trials in a variety of leadership roles. I am Chair of CME committee, Asia Pacific Society of Nephrology Chair the Oceania and South East Asia Regional Board, International Society of Nephrology, which sees me central to the shaping of education and global policy for kidney health.

Academic Record and Qualifications

Degrees and Professional Qualifications

2011	Doctorate of Philosophy, University of Sydney PhD
2009	Fellow of the Royal Australasian College of Physician
2007	Awarded Specialist status in Internal Medicine and Nephrology by Academy Malaysia Medical Council, Malaysia.
2002	Membership of Royal College of Physician, MRCP (UK).
1999	MB.BS Manipal Academy of Higher Education, India

Current Positions/ Appointments

2022+	Associate Professor of Medicine, University of Sydney
2022+	Senior Consultant Nephrologist, Concord Repatriation General Hospital, Sydney Local Health District (SLHD)
2011+	VMO Nephrologist, Sydney Adventist Hospital

Past Appointments/Positions:

2021-22	Conjoint Senior Associate Professor in Medicine, University of New South Wales
2021-22	Clinical Associated Professor in Medicine, University of Sydney
2013-22	Senior Research Fellow, The George Institute for Global Health
2020-22	Senior staff specialist, Royal North Shore Hospital (RNSH), Northern Sydney Local Health District (NSLHD).
2016-22	Director, Renal Clinical Trial Unit, RNSH
2011-21	Senior Clinical Lecture, University of Sydney
2011-22	Post-doctoral Research Fellow, Kolling Institute of Medical Research
2017-20	Director of Renal Dialysis Service, Sydney Adventist Hospital
2013-20	Staff Specialist in Renal Medicine, Royal North Shore Hospital
2010-13	Director of Physician training and Clinical Supervisor, RNSH

2010-13	Locum Renal Physician and General Medicine, Royal North Shore Hospital
2010-11	Locum Renal Physician, Royal North Shore Hospital
2008-11	Clinical Associate, University of Sydney
2008-09	Senior Hospital Scientist in Renal Research, Kolling Institute
2009-13	VMO Renal Physician, Manly Hospital
2003-04	Research Fellow, Juntendo University, Tokyo, Japan.

Key Awards

2017	Ramsay Research and Teaching Fund Awards
2016	Diabetes Australia Millennium Type 2 Diabetes Research Awards (DART)
2015	Ramaciotti Establishment Awards
2014	Young Investigator Award, Asia Pacific Congress of Nephrology, Tokyo
2014	Finalist Kidney Health Australia, Clinical Science, Australian and New Zealand Society of Nephrology
2013	Asian Young Nephrologist awards, Japanese Society of Nephrology
2011	Finalist, Young Investigator Award, Australian and New Zealand Society of Nephrology
2011	Early Career Investigator Award, RNSH/UTS/USYD/Kolling Institute combined.
2008	Young investigator award, RNSH/UTS/USYD/Kolling Institute combined.
2007	Endeavour International Post-graduate Research Scholarship and International Post-graduate Awards, University of Sydney
2005	Young investigator awards, Malaysia Society of Nephrology
1999	Best outgoing medical graduate 1999
	First in Internal Medicine
	First in 1 st year MBBS
	First in Physiology
	First in Anatomy

Education and Supervision

I supervise, mentor, train and examine medical students, resident, basic physician trainees and advanced renal trainees on regular basis ever since I was a resident.

A) Medical Students

- a) Lecture (Nephrotoxicity (2015), electrolytes and kidneys (2011) and Kidney physiology to 3rd year Masters of Physiology (Oct 2014).
- b) Bedside clinical teaching for the Renal Urology block, Northern Clinical School (2006 to 2021) and at the Sydney Adventist Clinical School (2018-2020).
- c) Problem Based Learning (PBL): 2008, 2009
- d) Communication skill (Med 2): 2010
- e) Summative assessments and objective structured clinical examination (OSCE)- 2007, 2008, 2019 & 2020.
- f) Sydney Medical Program assessment: Professional and Personal Development (PPD): 2019+

B) Post Graduate Education & Professional training

- a) I designed and coordinated 12-week clinical training and 6 months written-exam preparatory training program for the Basic Physician Trainees.
- b) I am an accredited supervisor for the Royal Australasian College of Physicians (RACP).
- c) I adopted and implemented the College recommended Physician Readiness for Expert Practice (PREP) and is familiar with its education tools including Program including learning Needs Analysis (LAN), Mini- CEX and Significant Incident Analysis.
- d) I am the Program Director for the Nephrology and Transplantation update course, Australia New Zealand Society of Nephrology (ANZSN) since 2017 to 2021.
- e) Program development for the Basic and Advanced Course for the Renal Advanced Trainee, and the Haemodialysis Academy.
- f) Scientific Program Co-Chair, the Asia Pacific Congress of Nephrology, Thailand (2021).
- g) Program Co-Chair of the Nephrology Biennial Review Course, World Congress of Nephrology, Melbourne (2018).
- h) Establishment of Australian New Zealand Society of Nephrology (ANZSN) Kidney e-Learning Hub (www.kelh.org.au) i.e. E-learning portal essential for the ANZSN to deliver its core business of education, training and research to the ANZSN membership. I have contributed to the Report for the pilot phase of KELH in June 2020, which led to the Council's decision to establish the ANZSN Website Advisory Panel (panel member) to conduct an independent vendor assessment process and redesign the ANZSN website incorporating the key features of KELH in the new website.

C) Supervision of Higher Degree by Research

- a) 2021 (12 months) International Society of Nephrology
- b) 2022+ PhD candidature: Dr. Dana Kim (Primary supervisor)
- c) 2020+ PhD candidature: Dr. Eveline Staube (Co-supervisor)
- d) 2019-20, Visiting Research Fellow (Japan): Dr. Megumi Oshima (joint-supervisor)
- e) 2017-21: PhD in Research: Dr. May YM Wong, titled "Novel anti-fibrotic agents in acute and chronic kidney disease" (Co-supervisor).
- f) 2016-20: PhD in Research: Dr. Stefanie Stangenberg, titled "Fetal programming of chronic kidney disease and novel treatment targets of renal fibrosis" (Co-supervisor).
- g) Master of Medical Science (University Technology of Science): Annabel Lozinski (2013-15), J Zhang (2011-12).
- h) Systemic review mentor: Edmund Chung (advanced trainee 2020+) and Joshua Lee (Master of Science in Clinical Epidemiology (University of Sydney (2017-2020)

D) International reputation in education and training:

2022+ Chair, Education Committee, Asia Pacific Society of Nephrology (APSN).

2021-22 Deputy Chair of the Education Committee, APSN.

2019-21 Member of the Education and Training Committee for the Australian New Zealand Society of Nephrology (ANZSN) that advise the Council through Royal Australasian College of Physicians and other relevant bodies, on the devolvment and endorsement of education programs related to the practice and research of nephrology.

2019-21 Member of the Scientific Program and Awards Committee of ANZSN that design the Scientific and clinical program run by ANZSN and oversee the Society's travel grants and award program.

- 2014 20th November: Represented University of Sydney for a scientific meeting with Senior Academics from Chulalongkorn University, Thailand.
- 31st July to 1st August: University representative to a Joint Symposium “In search of excellence: joint research projects leading to clinical excellence” between University of Sydney and Chulalongkorn University, Thailand.

Research

My specific areas of research interest are interventions to slow the progression of chronic kidney disease, reducing its complications especially cardiovascular burden, IgA nephropathy, diabetic kidney disease and biomarker research.

Research output and quality: I have 58 publications including 53 journal articles, 5 book chapters and 2 guidelines.

- I have a h-index of 16 and have accumulated 660 citations (19 per publication). Five of my publications have been cited >50 times (e.g. a Diabetes Care article, which I led as the first author, has received >119 citations to date).
- My publications have a field-weighted citation of 2.68 (SciVal Dec 2020)
- 54% of my publications are in the top 10% of journals worldwide and nearly 60% of my publications are co-authored with international collaborators.

Research funding: In the past 10 years, I have received over \$6 million in peer-reviewed project funding including 2 NHMRC project grants (TRACK trial APP1162375 (CIG), 2019-23, \$5.5 million) and (APP1144619, 2018-22, CIE \$500K), Diabetes Australia Millennium Grant (CIA 2016-18, \$150K), Ramsay Research and Teaching Fund (CIA 2017-18, \$56K), perpetual Ramaciotti grants (CIA 2014-15, \$75K), and Basic Research Grant (equivalent \$34K, AI) which is an international collaboration with Malaysia.

Research leadership

- Director of the Renal Clinical Trial Unit at RNSH where I lead a team of trialists and 3 study coordinators in the management of 27 clinical trials.
- Co-chair the Clinical Trial and Research Translation Enabler Committee, Kolling Institute which is responsible for providing leadership, strategic direction and advice to facilitate the removal of barriers to clinical trials, research translation and commercialisation for the Kolling Institute and the Northern Sydney Local Health District (NSLHD).
- Expert input for the Targeted Translation (TTRA) Diabetes & Cardiovascular Disease: 2021 Roundtable Consultation to identify and prioritise unmet needs in diabetes and cardiovascular disease which will inform the second round of Research Projects funding that administer \$47 million Medical Research Future Fund (4 August 2021).
- Medical Advisory Board Committee: DIMERIX-200 (2020+), CSL-Behring (2020+), Otsuka (2021+), Chinook (2021+)
- Steering Committee member: CSL346_2001 trial (2019+), TESTING, ASPIRED, TRACK, REDUCCTION, REMOVAL-HD, ACHIEVE, DIAMOND, PROTECT, DUPLEX, and GRITS trials.

- Global Project Director for TESTING (503 participants, IgA nephropathy trial- the largest randomized controlled trial in IgAN, 2013+) and ASPIRED (9000 participants, aspirin use in dialysis (2018+))
- Australia National Lead: PROTECT, DUPLEX and ARMETIS-IgAN trials.
- Regional Scientific Lead for the ASCEND program (CV safety and efficacy of a HIF-1a inhibitor vs recombinant erythropoietin in treatment of anaemia associated with CKD in people not receiving dialysis (ASCEND-ND, n=2964, 62 sites) and on dialysis (ASCEND-D, n=3690, 84 sites), SONAR (n=5107, 689 sites), MOSAIC (n=310, 105 sites), ENVISION (n=200, 39 sites), and FLAIR (n=1500, 180 sites) trials.
- Global Scientific Lead for DIMERIX-ACTION3 and a phase 3 OTSUKA IgAN trial.
- Site Principal Investigator: PROTECT, DUPLEX, ALIGN, AFFINITY, IONS-IgAN, ENVISION, TRACK, GRIT, DIMERIX ACTION-3, ARMETIS-IgA and ACHIEVE trials.

Industry collaboration and leadership

- 2009+ Through industry collaboration with Pharmaxis Ltd, I led the research that supported by an ARC-linkage grant (2013-2016). One of the studied anti-fibrotic agents, PXS4728A was acquired by Boehringer Ingelheim for a value AUD\$39 million (Euro\$750million). The agent is currently being tested in a phase 2 clinical trial. The sustained industry collaboration and partnership with Pharmaxis Ltd is reflected by an NHRMC development grant application in 2016, and MRFF drug discovery application for a phase 1c study to evaluate safety, pharmacokinetics and pharmacodynamics of PXS-5382 in patients post renal transplantation (MRFT000025, under review).
- 2020+ Two provisional patents (APN 2021901061& APN 2021901144) were submitted as the outcomes of a NHRMC Project Grant APP1144619 for which I am a CI, and lead to the discovery of novel diagnostic method using hyperspectral autofluorescence technique and innovative deep learning-based technique known as moRphology - dEep Learning Imaging Cells (RELIC).

Contribution to discipline regional and international level

- 2021+ Chair of Regional Board for Oceania and South East Asia, International Society of Nephrology (ISN)
- 2021+ Member of the Stakeholder and Engagement Subcommittee, International IgA Nephropathy Network Research Committee (IIgANN)
- 2019+ Executive committee member of the International Association Congress of Nephrology (IACN).
- 2019-20 Deputy Chair of ISN Regional Board for Oceania and South East Asia
- 2019+ A member of the International IgA Nephropathy Network: a collaborative network using global data from China, Canada, India, Europe, Japan, South American for research.
- 2017+ A collaboration with Prof Xue Qing Yu, Dean of Medicine, GuangDong Provincial People's Hospital, China for the ASPIRED trial- a project fully funded by for a large-simple pragmatic trial to determine the safety and efficacy of low dose aspirin in 9000 participants on maintenance dialysis over 5 years.
- 2016+ Collaboration with University Malaya Medical Centre, Malaysia for a project "Association of Clinical and Genetic Markers with Erythropoietin Deficiency Anemia and Erythropoietin Stimulating Agents Treatment Response in Pre-Dialysis Chronic Kidney Disease response in pre-dialysis CKD".

Guidelines

- 2021+ KDIGO Controversies Conference on Novel Anemia Therapies: Pathophysiology of HIFs and effects beyond hemoglobin
- 2018-19 Clinical Practice Guidelines Recommendations, Asia Pacific Society of Nephrology focusing on lower-middle income countries
- 2017-18 Kidney Health Australia-CARI Guideline Recommendations for Infection Control for Haemodialysis Units

Editorial responsibility

- 2018+ Nephrology Editorial Board. Subject editor, Diabetic Kidney Disease (Clinical and Experimental).

Publications

1. Wong MG, Lv JC, Hladunewich MA, Jha V, Hooi LS, Monaghan H, Zhao MH, Barbour S, Reich H, Cattran D, Glassock R, Levin A, Jardine MJ, Wheeler DC, Woodward M, Billot L, Chan TM, Liu ZH, Johnson DW, Cass A, Feehally J, Floege J, Remuzzi G, Wu YF, Agarwal R, Zhang H and Perkovic. The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) study- trial design and baseline characteristics, American Journal of Nephrology (accepted for publication September 2021).
2. Mahbub S, Nguyen LT, Habibalahi A, Campbell JM, Anwer AG, Qadri UM, Gill A, Chou A, Wong MG, Gosnell ME, Pollock C, Saad S, Goldys EW. Non-invasive assessment of exfoliated kidney cells extracted from urine using multispectral autofluorescence features. Scientific Report, (accepted for publication 30 April 2021)
3. Tiong MK, Krishnasamy R, Smith ER, Hutchison CA, Ryan EG, Pascoe EM, Hawley CM, Hewitson TD, Jardine MJ, Roberts MA, Cho Y, Wong MG, Heath A, Nelson CL, Sen S, Mount PF, Vergara LA, Paul-Brent PA, Johnson DW, Toussaint ND. Effect of a medium cut-off dialyzer on protein-bound uremic toxins and mineral metabolism markers in patients on hemodialysis. Hemodial Int 2021.
4. Ethier I, Johnson DW, Bello AK, Ye F, Osman MA, Levin A, Harris D, Kerr P, Liew A, Wong MG, Lunney M, Saad S, Vieceilli AK. International Society of Nephrology Global Kidney Health Atlas: structures, organization, and services for the management of kidney failure in Oceania and South East Asia. kidney International Supplement 2021;11.
5. Oshima M, Hara A, Toyama T, Jun M, Pollock C, Jardine M, Harrap S, Poulter N, Cooper ME, Woodward M, Chalmers J, Perkovic V, Wong MG, Wada T. Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor. Kidney International Reports 2021;6:284-95.
6. O'Hara DV, Wong JK, Cooper B, Wong G, Wong MG, Cheikh Hassan HI. Lessons for the clinical nephrologist: ureteric obstruction secondary to blood clot after kidney biopsy. J Nephrol 2021.
7. Chatterton S, Williams S, Nahar K, Menzies AM, Wong MG. Immunotherapy-related acute kidney injury: Kidney biopsy or not? Nephrology 2021;26:89-90.
8. Wong MYW, Saad S, Wong MG, Stangenberg S, Jarolimek W, Schilter H, Zaky A, Gill A, Pollock C. Semicarbazide-sensitive amine oxidase inhibition ameliorates albuminuria and

glomerulosclerosis but does not improve tubulointerstitial fibrosis in diabetic nephropathy. PLoS ONE 2020;15.

9. Yugavathy N, Huri HZ, Kun LS, Bin Abdul Gafor AH, Wong MG, Bavanandan S, Seng WH. Clinical and genetic markers of erythropoietin deficiency anemia in chronic kidney disease (predialysis) patients. Biomark Med 2020;14:1099-108.
10. Ethier I, Cho Y, Hawley C, Pascoe EM, Vieceilli AK, Campbell SB, van Eps C, Isbel NM, Cooper BA, Harris DC, Pollock CA, Wong MG, Johnson DW. Rate of decline in residual kidney function pre and post peritoneal dialysis initiation: A post hoc analysis of the IDEAL study. PLoS ONE 2020;15.
11. Toussaint ND, Pedagogos E, Lioufas NM, Elder GJ, Pascoe EM, Badve SV, Valks A, Block GA, Boudville N, Cameron JD, Campbell KL, Chen SSM, Faull RJ, Holt SG, Jackson D, Jardine MJ, Johnson DW, Kerr PG, Lau KK, Hooi LS, Wong MG et al. A randomized trial on the effect of phosphate reduction on vascular end points in CKD (improve-CKD). Journal of the American Society of Nephrology 2020;31:2653-66.
12. Liew A, Bavanandan S, Prasad N, Wong MG, Chang JM, Eiam-Ong S, Hao CM, Lim CY, Lim SK, Kook-Hwan OH, Okada H, Susantitaphong P, Lydia A, Tran HTB, Villanueva R, Yeo SC, Tang SCW. Asian Pacific Society of Nephrology Clinical Practice Guideline on Diabetic Kidney Disease – An Executive Summary. Nephrology 2020;25:809-17.
13. Liew A, Bavanandan S, Prasad N, Wong MG, Chang JM, Eiam-Ong S, Hao CM, Lim CY, Lim SK, Oh KH, Okada H, Susantitaphong P, Lydia A, Tran HTB, Villanueva R, Yeo SC, Tang SCW. ASIAN PACIFIC SOCIETY OF NEPHROLOGY CLINICAL PRACTICE GUIDELINE ON DIABETIC KIDNEY DISEASE. Nephrology (Carlton, Vic) 2020;25:12-45.
14. Krishnasamy R, Hawley CM, Jardine MJ, Roberts MA, Cho Y, Wong MG, Heath A, Nelson CL, Sen S, Mount PF, Pascoe EM, Vergara LA, Paul-Brent PA, Toussaint ND, Johnson DW, Hutchison CA. A trial evaluating mid cut-off value membrane clearance of albumin and light chains in hemodialysis patients: A safety device study. Blood Purification 2020;49:468-78.
15. Hultin S, Nahar K, Menzies AM, Long GV, Fernando SL, Atkinson V, Cebon J, Wong MG. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: A retrospective case series report. BMC nephrology 2020;21.
16. Cherney DZI, Dekkers CCJ, Barbour SJ, Cattran D, Abdul Gafor AH, Greasley PJ, Laverman GD, Lim SK, Di Tanna GL, Reich HN, Vervloet MG, Wong MG, Gansevoort RT, Heerspink HJL, investigators D. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. Lancet Diabetes Endocrinol 2020;8:582-93.
17. Wong MG, Ninomiya T, Liyanage T, Sukkar L, Hirakawa Y, Wang Y, Wyld MLR, Morton RL, Chadban S, Howard K, Jardine MJ. Physical component quality of life reflects the impact of time and moderate chronic kidney disease, unlike SF-6D utility and mental component SF-36 quality of life: An AusDiab analysis. Nephrology 2019;24:605-14.
18. Toyama T, Neuen BL, Jun M, Ohkuma T, Neal B, Jardine MJ, Heerspink HL, Wong MG, Ninomiya T, Wada T, Perkovic V. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. Diabetes Obes Metab 2019;21:1237-50.
19. Nguyen LT, Mak CH, Chen H, Zaky AA, Wong MG, Pollock CA, Saad S. Sirt1 attenuates kidney disorders in male offspring due to maternal high-fat diet. Nutrients 2019;11.

20. Jardine M, Commons RJ, de Zoysa JR, Wong MG, Gilroy N, Green J, Henderson B, Stuart RL, Tunnicliffe DJ, van Eps C, Athan E. Kidney Health Australia - Caring for Australasians with Renal Impairment guideline recommendations for infection control for haemodialysis units. *Nephrology* 2019;24:951-7
21. Wong MG, Thyne NL, Glastras S. Maternal obesity and offspring risk of chronic kidney disease. *Nephrology* 2018;23:84-7.
22. Wong MG, Jardine M, Perkovic V. Glucose lowering and the kidney: are all drug classes equal? *The Lancet Diabetes and Endocrinology* 2018;6:835-7.
23. Wong MG, Heerspink HJL, Perkovic V. ACCORDION: Ensuring that we hear the music clearly. *Clinical Journal of the American Society of Nephrology* 2018;13:1621-3.
24. Stangenberg S, Saad S, Schilter HC, Zaky A, Gill A, Pollock CA, Wong MG. Lysyl oxidase-like 2 inhibition ameliorates glomerulosclerosis and albuminuria in diabetic nephropathy. *Scientific Reports* 2018;8
25. Rådholm K, Wu JH, Wong MG, Foote C, Fulcher G, Mahaffey KW, Perkovic V, Neal B. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – A systematic review. *Diabetes Research and Clinical Practice* 2018;140:118-28.
26. Krishnasamy R, Hawley CM, Jardine MJ, Roberts MA, Cho YJ, Wong MG, Heath A, Nelson CL, Sen S, Mount PF, Pascoe EM, Darssan D, Vergara LA, Paul-Brent PA, Toussaint ND, Johnson DW, Hutchison CA. Design and methods of the REMOVAL-HD study: A tRial Evaluating Mid cut-Off Value membrane clearance of Albumin and Light chains in HaemoDialysis patients. *BMC nephrology* 2018;19.
27. Miller HM, Tong A, Tunnicliffe DJ, Campbell D, Pinter J, Commons RJ, Athan E, Craig JC, Gilroy N, Green J, Henderson B, Howell M, Stuart RL, van Eps C, Wong MG, de Zoysa J, Jardine MJ. Identifying and integrating patient and caregiver perspectives for clinical practice guidelines on the screening and management of infectious microorganisms in hemodialysis units. *Hemodialysis International* 2017;21:213-23.
28. Lv J, Zhang H, Wong MG, Jardine MJ, Hladunewich M, Jha V, Monaghan H, Zhao M, Barbour S, Reich H, Cattran D, Glassock R, Levin A, Wheeler D, Woodward M, Billot L, Chan TM, Liu ZH, Johnson DW, Cass A, et al. Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial. *JAMA* 2017;318:432-42.
29. Glastras SJ, Chen H, Tsang M, Teh R, McGrath RT, Zaky A, Chen J, Wong MG, Pollock CA, Saad S. The renal consequences of maternal obesity in offspring are overwhelmed by postnatal high fat diet. *PLoS ONE* 2017;12.
30. Wong MG, Perkovic V. Knowing what we do not know: statin therapy in advanced chronic kidney disease. *Lancet Diabetes Endocrinol* 2016;4:801-3.
31. Sukkar L, Hong D, Wong MG, Badve SV, Rogers K, Perkovic V, Walsh M, Yu X, Hillis GS, Gallagher M, Jardine M. Effects of ischaemic conditioning on major clinical outcomes in people undergoing invasive procedures: systematic review and meta-analysis. *BMJ* 2016;355:i5599
32. Liyanage T, Ninomiya T, Wang A, Neal B, Jun M, Wong MG, Jardine M, Hillis GS, Perkovic V. Effects of the Mediterranean Diet on Cardiovascular Outcomes-A Systematic Review and Meta-Analysis. *PLoS One* 2016;11:e0159252.
33. Glastras SJ, Chen H, Teh R, McGrath RT, Chen J, Pollock CA, Wong MG, Saad S. Mouse models of diabetes, obesity and related kidney disease. *PLoS ONE* 2016;11.

34. Gallagher M, Wong MG, Perkovic V. ALTITUDE: Defining a ceiling for blockade of the renin-angiotensin system? *The Lancet Diabetes and Endocrinology* 2016;4:289-90.
35. Zhang J, Wong MG, Wong M, Gross S, Chen J, Pollock C, Saad S. A cationic-independent mannose 6-phosphate receptor inhibitor (PXS64) ameliorates kidney fibrosis by inhibiting activation of transforming growth factor- β 1. *PLoS ONE* 2015;10.
36. Wong MG, Wanner C, Knight J, Perkovic V. Lowering cholesterol in chronic kidney disease: Is it safe and effective? *European Heart Journal* 2015;36:2988-95.
37. Wong MG, Perkovic V. Reducing the excess vascular risk associated with chronic kidney disease. *Medicographia* 2015.
38. Stangenberg S, Chen H, Wong MG, Pollock CA, Saad S. Fetal programming of chronic kidney disease: The role of maternal smoking, mitochondrial dysfunction, and epigenetic modification. *American Journal of Physiology - Renal Physiology* 2015;308:F1189-F96.
39. Glastras SJ, Wong MG, Chen H, Zhang J, Zaky A, Pollock CA, Saad S. FXR expression is associated with dysregulated glucose and lipid levels in the offspring kidney induced by maternal obesity. *Nutrition and Metabolism* 2015;12.
40. Wong MG, Pollock CA, Cooper BA, Branley P, Collins JF, Craig JC, Kesselhut J, Luxton G, Pilmore A, Harris DC, Johnson DW. Association between GFR estimated by multiple methods at dialysis commencement and patient survival. *Clinical Journal of the American Society of Nephrology* 2014;9:135-42.
41. Wong MG, Perkovic V. CVD in chronic kidney disease: what do we know? *Cardiology Today* 2014;4:8-12
42. Wong MG, Pollock CA. Biomarkers in kidney fibrosis: Are they useful? *Kidney international supplements* 2014;4:79-83.
43. Wong MYG, Saad S, Zhang J, Gross S, Jarolimek W, Schilter H, Chen JA, Gill AJ, Pollock CA, Wong MG. Semicarbazide-Sensitive amine oxidase (SSAO) inhibition ameliorates kidney fibrosis in a unilateral ureteral obstruction murine model. *American Journal of Physiology - Renal Physiology* 2014;307:F908-F16
44. Knight J, Wong MG, Perkovic V. Optimal targets for blood pressure control in chronic kidney disease: The debate continues. *Current Opinion in Nephrology and Hypertension* 2014;23:541-6.
45. Al-Odat I, Chen H, Chan YL, Amgad S, Wong MG, Gill A, Pollock C, Saad S. The impact of maternal cigarette smoke exposure in a rodent model on renal development in the offspring. *PLoS ONE* 2014;9.
46. Wong MYW, Saad S, Pollock C, Wong MG. Semicarbazide-sensitive amine oxidase and kidney disease. *American Journal of Physiology - Renal Physiology* 2013;305:F1637-F44.
47. Wong MG, Perkovic V, Woodward M, Chalmers J, Li Q, Hillis GS, Yaghobian Azari D, Jun M, Poulter N, Hamet P, Williams B, Neal B, Mancia G, Cooper M, Pollock CA. Circulating bone morphogenetic protein-7 and transforming growth factor- β 1 are better predictors of renal end points in patients with type 2 diabetes mellitus. *Kidney International* 2013;83:278-84.
48. Saad S, Zhang J, Yong R, Yaghobian D, Wong MG, Kelly DJ, Chen XM, Pollock CA. Role of the EGF receptor in PPAR γ -mediated sodium and water transport in human proximal tubule cells. *Diabetologia* 2013;56:1174-82.
49. Johnson DW, Wong MG, Cooper BA, Branley P, Bulfone L, Collins JF, Craig JC, Fraenkel MB, Harris A, Kesselhut J, Li JJ, Luxton G, Pilmore A, Tiller DJ, Harris DC, Pollock CA.

- Effect of timing of dialysis commencement on clinical outcomes of patients with planned initiation of peritoneal dialysis in the IDEAL trial. *Perit Dial Int* 2012;32:595-604.
50. Wong MG, Panchapakesan U, Qi W, Silva DG, Chen XM, Pollock CA. Cation-independent mannose 6-phosphate receptor inhibitor (PXs25) inhibits fibrosis in human proximal tubular cells by inhibiting conversion of latent to active TGF- β 1. *American Journal of Physiology - Renal Physiology* 2011;301:F84-F93.
 51. McGregor A, Ogwu C, Uppal T, Wong MG. Spontaneous subcutaneous emphysema and pneumomediastinum during second stage of labour. *BMJ Case Reports* 2011.
 52. Amarasekara C, Uppal T, Wong MG. Post partum flare in a patient with hereditary aniogoedema. *Sri Lanka Journal of Obstetrics and Gynaecology* 2011;33:166-8
 53. Wong MG, Suzuki Y, Tanifuji C, Akiba H, Okumura K, Sugaya T, Yamamoto T, Horikoshi S, Si YT, Pollock C, Tomino Y. Peritubular ischemia contributes more to tubular damage than proteinuria in immune-mediated glomerulonephritis. *Journal of the American Society of Nephrology* 2008;19:290-7
 54. Tanifuji C, Suzuki Y, Wong MG, Horikoshi S, Sugaya T, Ruiz-Ortega M, Egido J, Tomino Y. Reactive oxygen species-mediated signaling pathways in angiotensin II-induced MCP-1 expression of proximal tubular cells. *Antioxid Redox Signal* 2005;7:1261-8.

Books/Chapters

1. Damasiewicz MJ, Wong MG, Kerr PG. Chapter 40: Haemodialysis treatment: choice of membrane type and modality. *Evidence-Based Nephrology*. Wiley. Accepted for publication October 2020
2. Wong MG and Pollock C. Chapter 24: Secondary diseases of the Kidney: Diabetic Nephropathy. *Evidence-Based Nephrology*. Wiley. Accepted for publication October 2020
3. Mather A and Wong MG Chapter title: Renovascular Hypertension, Pregnancy-Related Hypertension and Thrombotic Microangiopathies, Surjit Tarafdar. Book *Nephrology: A Comprehensive Guide to Renal Medicine*. Wiley-Blackwell. April 2020
4. Chapter Update: Wong MG, Cooper B, Pollock C. Chapter 143: Preparation for renal replacement therapy. *Oxford Textbook of Clinical Nephrology*. 4 ed: Oxford University Press; December 2016:1148-56.
5. Wong MG, Cooper B, Pollock C. Chapter 143: Preparation for renal replacement therapy. *Oxford Textbook of Clinical Nephrology*. 4 ed: Oxford University Press; 2015:1148-56.

Invited speaker

1. Special focus on IgA nephropathy: key insights from trials. Title: PROTECT trial, 6th virtual Kidney Disease Clinical Trialists (KDCT) workshop, 29th to 30th October 2021.
2. Invited faculty speaker, Asia-Pacific chapter of GlomCon Virtual Fellowship, “Treatment of IgA nephropathy” 14th January 2021 <https://edu.glomcon.org/fellowship>
3. Virtual symposium speaker “Clinical practice guidelines for diabetic kidney disease in Asia Pacific region”, Asia Pacific Congress of Nephrology, Thailand August 2021.
4. Invited Virtual Webinar Speaker: Renal Trial in Asia-Pacific: Opportunities and Advancements. 29th Oct 2020.
5. “Resistant hypertension and management” and glomerulonephritis workshop facilitator, Virtual Advance Trainee Basic Course by ANZSN, Oct 2020.

6. Invited speaker “Role of endothelin antagonist receptor inhibitors in renal disease”, Nephrology and Transplantation Update Course, 54th ANZSN Annual Scientific Meeting, Virtual Meeting 28th Nov to 2nd December 2020
7. Invited speaker “Role of SGLT-2 inhibitor in non-diabetic proteinuric renal disease”, 3rd International Congress of Chinese Nephrologists (ICCN), December 5-8, 2019, Nanjing, China.
8. Invited speaker, “Role of antiplatelet & anticoagulant for CV protection in advanced CKD”, Annual Meeting of Kidney Disease Prevention and Treatment, 20th to 22nd June 2019, Guangzhou, China.
9. Invited speaker, “Antiplatelet and anticoagulant management in EKSD”, Blood Purification Forum, Chinese Society of Nephrology, Chengdu, 25th to 28th May, 2019.
10. Invited speaker, “Optimal management for anaemia of CKD patients and novel ESAs” Korea Society Nephrology meeting, Seoul, 23rd to 26th May 2019.
11. Invited speaker, “Biennial Nephrology Update Course, Steroid in IgA nephropathy: Friend or foe?” April 2019, World Congress of Nephrology, Melbourne.
12. Invited speaker for the 2nd International Congress of Chinese Nephrologist (ICCN): From prevention to Innovation. Taipei, Taiwan 8-10th December 2017.
13. “Update in therapies for IgA nephropathy”, Nephrology and Transplantation Update Course, ANZSN Annual Scientific Meeting, Darwin, 2-6th September 2017.
14. The 8th Asia Pacific Chapter Meeting of International Society for Peritoneal Dialysis, “Potential of Asian Pacific Region for Large Scale Clinical Trial” and “Cardiovascular Disease Management in Dialysis”, Guang Zhou, China, 22nd to 25th March 2017.
15. AdAlta Fibrosis symposium. “Renal Fibrosis and Chronic Kidney Disease” 21st February, Melbourne 21st February 2017.
16. 2nd International Cardio Renal symposium, Guang Zhou, China. “High Impact Renal Publications” and “Lipids lowering in Kidney disease”, 8th-9th February 2017.
17. Concord Hospital/ Royal Prince Alfred Hospital Combined Nephrology meeting titled, “Corticosteroids use in IgA nephropathy- an unresolved dilemma?” Concord, Australia, 1st September 2016.
18. Renal meeting on “Outcomes of the TESTING study” Royal Adelaide Hospital, Adelaide, Australia, 13th October 2016.
19. XVIII International Congress on Nutrition and Metabolism in Renal Disease, Okinawa, Japan 19-23 April 2016. "Lowering cholesterol in CKD: Is it safe and effective?" (Invited speaker)
20. 32nd Congress of Malaysian Society of Nephrology, 29 April-1 May 2016, Johor Bahru, Malaysia. Two talks A) Recent advances in IgA: From bench to bedside B) Treatment targets for DKD – beyond RAS blockade (invited speaker)
21. 1st International Cardio Renal symposium, Sydney, Australia, 8-9 May 2015 “The role of endothelin-1 receptor antagonist in cardiac and renal disease”.
22. 16th International Amine Oxidase Conference, 14-15 July 2014. Sydney, Australia. Title” Semicarbazide Amine Oxidase and Kidney disease”(Invited speaker)
23. The World Congress of Nephrology (WCN) titled “Advances in limiting tubulointerstitial injury”, Hong Kong, June 2013.(Invited speaker)
24. The Division of Renal Medicine, First Hospital of Peking University, Beijing, China. “Therapeutic options in delaying progression of diabetic nephropathy: Is there anything new?”, 2nd August 2012.(invited speaker)

25. Plenary speaker for “A review of updates in nephrology in 2011”, Hearts and Minds Cardiovascular Conference, Sydney, Australia, October 2011. (Invited speaker)
26. Kidney Health Australia, KCAT workshop ‘Management of Stage 3 CKD in general practice’, Manly Warringah Division of General practice, Manly, Australia, 27th October 2010.
27. NSW Rural Doctors Network for the Obstetrics Procedural Conference, “Management of Hypertension in Pregnancy”, Sydney, Australia, September 2010.
28. “Antifibrotic Therapy in Kidney Disease: Are We Any Closer in Finding A Solution?” PReSS seminar Kolling Institute of Medical Research, RNSH, 3^{1st} July 2009
29. “Role of Cationic Independent Mannose 6-Phosphate inhibitor (PSX25) in Renal Fibrosis?” Invited speaker by Pharmaxis Ltd, 20 Rodborough Road, Frenchs Forest, 7th July 2009.

Published abstract/ poster presentation

1. Camargo M, King A, Wong MG, Glicklich A. Atrasentan in Patients with Proteinuric Glomerular Diseases (The AFFINITY Study). Renal Week, American Society of Nephrology, 4-7th November 2021.
2. Lv, JC, Wong MG,....” The TESTING study: steroids vs placebo in high risk IgA nephropathy”, Late-breaking trial, Renal Week, American Society of Nephrology, 5th November 2021.
3. Chung E, Badve S...Wong MG. “The Efficacy and Safety of Endothelin Receptor Antagonist on Renal outcomes: an Updated Systematic Review of Randomized Trials” ASN Kidney Week 2019, Abstract ID# 3236820
4. Wong MG, Cooper B, et al. The effect of dialysis modality switch on residual renal function in patients with stage 5 chronic kidney disease. A post hoc analysis from the IDEAL trial. 14th Asian Pacific Congress of Nephrology, 2014, Tokyo.
5. Zhang J, Wong MY, Wong MG et al. The cationic-independent mannose 6-phosphate receptor inhibitor (PXS64) ameliorates kidney fibrosis through transforming growth factor- β 1 and phosphor-Smad 2 signalling pathways. 14th Asian Pacific Congress of Nephrology, 2014, Tokyo.
6. Wong MY...Wong MG. Semicarbazide-sensitive amine oxidase (SSAO) inhibition ameliorates kidney fibrosis in a unilateral ureteral obstruction murine model. 14th Asian Pacific Congress of Nephrology, 2014, Tokyo.
7. Wong MG, Pollock C et al. The association between glomerular filtration rates estimated by multiple methods at dialysis commencement and patient survival in the IDEAL trial, ANZSN, 2013, Brisbane.
8. Wong M, Saad S, Pollock C and Wong MG. Semicarbazide-sensitive amine oxidase inhibitor inhibits extracellular matrix deposition in kidney fibrosis. ANZSN, 2013, Brisbane.
9. Saad S, Chen H, Pollock CA and Wong MG. Maternal obesity related renal injury in mother and offspring is mediated through down regulation of renal farnesoid X receptor (FXR) expression. Abstract no. O125. The Amgen Basic Science Award Category. ANZSN, 2012, New Zealand. Abstract No. O125
10. Wong MG, Clayton P, *et al*. Does early nephrology care matter? A retrospective comparison study of the initiating dialysis early and late (IDEAL) study late starters versus ANZDATA late starters. Abstract No. O29, ANZSN, 2012, New Zealand.
11. Cooper BA, Wong MG, *et al*. When is the ideal time to start a home based dialysis therapy? Abstract No. O84, ANZSN, 2012, New Zealand.

12. Wong MG, Li Q, *et al.* Circulating BMP-7 (BMP7) and TGF- β 1 (TGF β 1) as potential biomarkers for renal endpoint in patients with Type 2 Diabetes Mellitus. Young Investigator Award Category. The ANZSN, 2011, Adelaide, Australia. Abstract No. 002.
13. Wong MG, Qi Weier, Chen XM, Perkovic V *et al.* Circulating bone morphogenetic protein-7 (BMP7) and transforming growth factor- β 1 (TGF β 1) as potential biomarkers for renal endpoint in patients with Type 2 Diabetes Mellitus. Early Career Research Category. The Annual Scientific Research Meeting, RNSH/UTS/USYD/Kolling Institute combined. 2011.
14. Wong MG, Saad S, Qi W, Chen XM, Pollock CA. Activation of Farnesoid X receptors (FXR) inhibits extracellular matrix (ECM) deposition in human kidney proximal tubular epithelial cells (PTCs). ANZSN 2010, Perth, Western Australia.
15. Saad S, Yong R, Wong MG, *et al.* The role of EGF receptor in mediating peroxisome proliferator activated receptors gamma induced sodium and water transport in human proximal tubule cells. ANZSN, 2009, Hobart, Tasmania. Abstract No. 131.
16. Wong MG, Sumual S, *et al.* Effects of Mannose 6-phosphate receptor inhibitor (PSX25) in TGF- β 1 production in HK2 cells in high glucose and hypoxic conditions. ASN, 2009, San Diego, USA. Abstract No. SA-PO2935.
17. Wong MG, Sumual S, *et al.* Role of Mannose 6-phosphate receptor inhibitor on active TGF- β 1 production in HK2 cells. ANZSN, 2009, Hobart, Tasmania. Abstract No. 125
18. Wong MG, Qi W, *et al.* Mesenchymal Epithelial Transdifferentiation Action of BMP-7 is inhibited by TGF- β 1 and KLF-6 via Suppression of BMP receptors of Expression in Human Kidney. WCN 2009, Milan, Italy. Abstract No: Sa248.
19. Wong MG, Sumual S, *et al.* Effects of Mannose 6-phosphate receptor inhibitor (PSX25) in transforming growth factor β 1 production in HK2 cells in high glucose and hypoxic conditions. ASN 2009, San Diego, USA. Abstract No. SA-PO2935.
20. Wong MG, Qi Weier, *et al.* Mesenchymal epithelial transition (MET) action of BMP-7 is inhibited by TGF- β 1 and KLF-6 via suppression of bone morphogenetic protein receptors expression in human proximal tubular cells. Young Investigator Category. The ASM RNSH/UTS/USYD/Kolling Institute, 2008: Abstract No. O12.
21. Wong MG, Qi Weier, *et al.* Bone morphogenetic protein receptors and its interaction with TGF β 1 and high glucose in human proximal tubule cells. The Annual Scientific Research Meeting, RNSH/UTS/USYD/Kolling Institute, 2007.
22. Wong MG, Yusuke S, Pollock CA *et al.* Relative Contribution of Hypoxia And Proteinuria in Tubulointerstitial Injury in Immune Mediated Glomerulonephritis. The Annual Scientific Research Meeting, RNSH / UTS/ USYD/ Kolling Institute Combined. 2006 . Abstract no. O25
23. Wong MG, Yusuke S, Pollock CA, *et al.* Peritubular Ischemia Has More Impact on Tubular Damage Than Proteinuria in Immune Mediated Glomerulonephritis. The 11th International Symposium on IgA Nephropathy, Tokyo. 2006
24. Wong MG, Yusuke S, *et al.* Kidney injury molecule-1: Its Expression in Various Murine Kidney Diseases. The 47th Annual Meeting Japanese Society of Nephrology, Japan. Conference 2004. Abstract No. EO-018.

Fellowships and Research Grants

2019	NHMRC Project Grant APP1162375 (CIF)	
-23	Treatment of cardiovascular disease with very low dose Rivaroxaban in Advanced Chronic Kidney disease (TRACK)	\$5,522,417.59
2018	NHRMC Project Grant APP1144619 (CIE)	

-22	Grant title: A novel diagnostic method to determine the likelihood of kidney fibrosis and progressive CKD in patients with diabetes mellitus and other forms of chronic proteinuric renal disease (2018-2022)	\$508,848
2017	Ramsay Research and Teaching Fund (CIA)	\$56,000
2016	DART Millennium type 2 Diabetes research (CIA)	\$150,000
2016	Fundamental Research Grant (UMMC, Malaysia) (AI) Grant title: Association of Clinical and Genetic Markers with Erythropoietin Deficiency Anemia and Erythropoietin Stimulating Agents Treatment Response in Pre-Dialysis Chronic Kidney Disease response in pre-dialysis CKD	\$35,000
2015	Perpetual Ramaciotti Establishment Award (CIA)	\$75,000
2014	Early Career Research Award (ERC), University of Sydney	\$25,000
2014	Jacquot Establishment Fellowship, RACP	\$75,000
2013	Early Career Research Fellowship Award (ECR) University of Sydney	\$25,000
2012	Don and Lorraine Jacquot Research Fellowship by RACP	\$90,000
2010	Don and Lorraine Jacquot Research Fellowship by RACP (6 months)	\$45,000
2009	University Post-graduate Awards (UPA), University of Sydney	\$19,000pa
2009	ISN World Congress of Nephrology (WCN) Travel Awards ANZSN ASM Travel Awards	\$2,500
2009	Beryl & Jack Jacobs Postgraduate research international travel award	\$2,500
2009	PRESS International Travel Awards	\$1,500
2009	Co-investigator of Neorecormon Research Grant Award	\$25,000
2008	ANZSN International travel grant, ASN renal week, Philadelphia, USA.	\$3,000
2007	Endeavour International Post-graduate Research Scholarship (EIPRS), University of Sydney	Tuition fees
2007	International Post-graduate Awards (IPA), University of Sydney.	\$19,000pa
2007	Top-up Scholarship, Northern Clinical School.	\$9,000pa
2007	ANZSN WCN Travel grant, Rio de Janeiro, Brazil.	\$2,500
2006	ANZSN Post graduate travel grant, Melbourne.	\$1,200
2005	ISN travel Award, World Congress Nephrology, Singapore	US\$1,000

Membership

1. Fellow Royal Australasian College of Physician (RACP), Australia.
2. Member of Royal College of Physician, United Kingdom.
3. Member of International Society of Nephrology (ISN).
4. Member of Australian and New Zealand Society of Nephrology (ANZSN).
5. Member of Transplant Society of Australian and New Zealand (TSANZ).
6. Affiliated member of American Society of Nephrology (ASN)
7. Member of Scientific Staff Council (SCC) Royal North Shore Hospital.
8. Member of the Academy of Medicine of Malaysia
9. Member of the Malaysia Society of Nephrology, Malaysia.



Updated on 4 March 2022